Ovid Therapeutics Inc
OVID0.482USD
-0.018-3.64%
Market hours （ET）Quotes delayed by 15 min
34.26MMarket Cap
LossP/E TTM
More Details of Ovid Therapeutics Inc Company
Ovid Therapeutics Inc. is a biopharmaceutical company. The Company is focused on improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. It is engaged in advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms. It develops OV888 (GV101), a potent and highly selective ROCK2 inhibitor, for the potential treatment of lesions associated with cerebral cavernous malformations and other brain disorders; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other psychiatric conditions. It also has interest in the development and commercialization of soticlestat, which is a cholesterol 24-hydroxylase inhibitor for Dravet and Lennox-Gastaut syndromes.
Company Info
Ticker SymbolOVID
Company nameOvid Therapeutics Inc
IPO dateMay 05, 2017
CEODr. Jeremy Max Levin, Ph.D.
Number of employees23
Security typeOrdinary Share
Fiscal year-endMay 05
Address441 Ninth Avenue, 14Th Floor
CityNEW YORK
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code10001
Phone12127764381
Websitehttps://ovidrx.com/
Ticker SymbolOVID
IPO dateMay 05, 2017
CEODr. Jeremy Max Levin, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Director
Independent Director
200.00K
--
Dr. Karen Bernstein, Ph.D.
Dr. Karen Bernstein, Ph.D.
Independent Director
Independent Director
20.00K
--
Ms. Barbara G. Duncan
Ms. Barbara G. Duncan
Independent Director
Independent Director
--
--
Dr. Jeremy Max Levin, Ph.D.
Dr. Jeremy Max Levin, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Kevin Fitzgerald, Ph.D.
Dr. Kevin Fitzgerald, Ph.D.
Independent Director
Independent Director
--
--
Mr. Bart Friedman, J.D.
Mr. Bart Friedman, J.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Jeffrey Rona
Mr. Jeffrey Rona
Chief Business and Financial Officer
Chief Business and Financial Officer
--
--
Ms. Margaret (Meg) Alexander
Ms. Margaret (Meg) Alexander
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Director
Independent Director
200.00K
--
Dr. Karen Bernstein, Ph.D.
Dr. Karen Bernstein, Ph.D.
Independent Director
Independent Director
20.00K
--
Ms. Barbara G. Duncan
Ms. Barbara G. Duncan
Independent Director
Independent Director
--
--
Dr. Jeremy Max Levin, Ph.D.
Dr. Jeremy Max Levin, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Kevin Fitzgerald, Ph.D.
Dr. Kevin Fitzgerald, Ph.D.
Independent Director
Independent Director
--
--
Mr. Bart Friedman, J.D.
Mr. Bart Friedman, J.D.
Lead Independent Director
Lead Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 23
Updated: Wed, Jul 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Takeda Pharmaceutical Co Ltd
10.59%
Levin (Jeremy M)
5.14%
BlackRock Institutional Trust Company, N.A.
5.04%
The Vanguard Group, Inc.
4.37%
Madison Avenue Partners LP
3.47%
Other
71.40%
Shareholders
Shareholders
Proportion
Takeda Pharmaceutical Co Ltd
10.59%
Levin (Jeremy M)
5.14%
BlackRock Institutional Trust Company, N.A.
5.04%
The Vanguard Group, Inc.
4.37%
Madison Avenue Partners LP
3.47%
Other
71.40%
Shareholder Types
Shareholders
Proportion
Investment Advisor
16.66%
Hedge Fund
13.33%
Investment Advisor/Hedge Fund
10.93%
Corporation
10.59%
Individual Investor
5.72%
Research Firm
1.65%
Bank and Trust
0.20%
Venture Capital
0.13%
Pension Fund
0.03%
Other
40.74%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
175
46.86M
65.90%
-15.45M
2025Q1
183
51.39M
72.29%
-10.07M
2024Q4
181
52.28M
73.63%
-8.46M
2024Q3
175
51.32M
72.31%
-10.19M
2024Q2
172
51.56M
72.67%
-6.81M
2024Q1
174
55.84M
78.97%
-6.53M
2023Q4
174
57.32M
81.09%
-4.46M
2023Q3
183
57.79M
81.95%
-5.02M
2023Q2
192
56.05M
79.62%
-3.53M
2023Q1
194
53.91M
76.62%
-6.14M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Takeda Pharmaceutical Co Ltd
7.53M
10.59%
--
--
Mar 31, 2025
Levin (Jeremy M)
3.65M
5.14%
-20.00
-0.00%
Apr 24, 2025
BlackRock Institutional Trust Company, N.A.
3.58M
5.04%
-59.44K
-1.63%
Mar 31, 2025
The Vanguard Group, Inc.
3.11M
4.37%
-39.30K
-1.25%
Mar 31, 2025
Madison Avenue Partners LP
2.47M
3.47%
-386.73K
-13.56%
Mar 31, 2025
Sio Capital Management, LLC
2.23M
3.14%
+1.23M
+123.20%
Mar 31, 2025
Acadian Asset Management LLC
2.09M
2.94%
+237.44K
+12.83%
Mar 31, 2025
Kennedy Capital Management LLC
1.73M
2.44%
+187.48K
+12.13%
Mar 31, 2025
Driehaus Capital Management, LLC
1.40M
1.97%
--
--
Mar 31, 2025
State Street Global Advisors (US)
1.37M
1.93%
-22.41K
-1.61%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Russell 2000 Growth ETF
0%
iShares Micro-Cap ETF
0%
ProShares UltraPro Russell2000
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
Proshares Ultra Russell 2000
0%
ProShares Ultra Nasdaq Biotechnology
0%
Invesco Nasdaq Biotechnology ETF
0%
Fidelity Enhanced Small Cap ETF
0%
ProShares Hedge Replication ETF
0%
Avantis Responsible US Equity ETF
0%
View more
iShares Russell 2000 Growth ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares Ultra Nasdaq Biotechnology
Proportion0%
Invesco Nasdaq Biotechnology ETF
Proportion0%
Fidelity Enhanced Small Cap ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Avantis Responsible US Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
